Northern Trust Corp Acquires 44,252 Shares of Vor Biopharma Inc. (NYSE:VOR)

Northern Trust Corp boosted its holdings in Vor Biopharma Inc. (NYSE:VOR) by 39.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 157,617 shares of the company’s stock after acquiring an additional 44,252 shares during the quarter. Northern Trust Corp owned 0.23% of Vor Biopharma worth $175,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in VOR. GABELLI & Co INVESTMENT ADVISERS INC. acquired a new stake in shares of Vor Biopharma during the 4th quarter worth about $33,000. Virtu Financial LLC acquired a new position in Vor Biopharma in the fourth quarter valued at about $60,000. XTX Topco Ltd bought a new stake in Vor Biopharma during the fourth quarter worth about $80,000. Finally, Lynx1 Capital Management LP acquired a new stake in shares of Vor Biopharma during the fourth quarter worth approximately $707,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Price Performance

VOR stock opened at $0.23 on Tuesday. The stock has a market capitalization of $29.28 million, a P/E ratio of -0.14 and a beta of -0.21. Vor Biopharma Inc. has a fifty-two week low of $0.13 and a fifty-two week high of $1.80. The business has a 50-day moving average of $0.48 and a 200-day moving average of $0.90.

Wall Street Analyst Weigh In

VOR has been the subject of a number of recent analyst reports. Jones Trading cut Vor Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. JMP Securities restated a “market perform” rating and issued a $6.00 target price on shares of Vor Biopharma in a research note on Friday, May 9th. Stifel Nicolaus reduced their price target on shares of Vor Biopharma from $12.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Oppenheimer restated an “outperform” rating and issued a $8.00 price objective on shares of Vor Biopharma in a research report on Friday, March 21st. Finally, Citizens Jmp downgraded shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 9th. Six equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $7.06.

Vor Biopharma Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.